Inactive

SPE2DP-22-R-0002 Sources Sought Notice for Zanamivir for Inhalation The Defense Logistics Agency (DLA) Troop Support is seeking sources capable of providing Zanamivir for Inhalation. DLA Troop Support... SPE2DP-22-R-0002 Sources Sought Notice for Zanamivir for Inhalation The Defense Logistics Agency (DLA) Troop Support is seeking sources capable of providing Zanamivir for Inhalation. DLA Troop Support is contemplating awarding a requirements contract with a one-year base period for Zanamivir for Inhalation 5MG Diskhaler 20 Count. The estimated quantity be ordered is 350,000 EA. These quantities may increase or decrease as quantities change. Must have FDA approval to sell Zanamivir for Inhalation before award of the contract. If your firm currently manufactures or distributes Zanamivir for Inhalation, please provide the following information: Place of manufacture Estimated annual capacity FDA registration Product name and description, including description of any special features Current unit sale price Estimated inventory level and storage requirements Shelf life (months) *** NEW PRODUCTS UNDER DEVELOPMENT*** For products under development, describe the current stage of development and whether or not the product has undergone independent laboratory testing or FDA testing/trials, etc. Firms and organizations that currently develop or manufacture Zanamivir for Inhalation or firms that have the technological, pharmaceutical, or manufacturing capabilities under development are invited to submit information to DLA Troop Support. Data obtained from this Request for Information (RFI) will be used by DLA Troop Support in making recommendations and decisions on the development of an appropriate planning and procurement strategy for Zanamivir for Inhalation. All information submitted shall remain with the U.S. Government and will not be returned. It will be kept confidential as allowed by relevant Federal law and will be eligible for additional special protections under the conditions of the Protected Critical Infrastructure Information (PCII) Program outlined in the Critical Infrastructure Act of 2002. This RFI does not commit the U.S. Government to issue a solicitation, make an award, or pay any costs associated with responding to this announcement. Your response to this RFI may be submitted electronically in PDF format and emailed Amanda.Doherty@dla.mil.

Inactive

The Defense Logistics Agency Troop Support is soliciting proposals for the supply of Zanamivir for Inhalation. A Firm Fixed Price Requirements contract is proposed with a one-year Base Period. All DoD... The Defense Logistics Agency Troop Support is soliciting proposals for the supply of Zanamivir for Inhalation. A Firm Fixed Price Requirements contract is proposed with a one-year Base Period. All DoD requirements will be placed on the proposed contract. The estimated quantity for the Base Period is 175,000 EA. Delivery is to be FOB Destination and delivered within 200 days from date of the delivery order. Contractor is required to deliver to various Contiguous United States (CONUS) locations provided at the time of the delivery order. All responsible sources may submit a proposal and shall be considered by the Agency. The successful contractor shall have Food and Drug Administration (FDA) approval to sell Zanamivir for Inhalation before award of the contract. Solicitation SPE2DP-21-R-0002 is expected to be issued on or around May 4, 2022 and can be found on the DLA Internet Bid Board System (DIBBS) at https://www.dibbs.bsm.dla.mil/. The point of contact is Amanda Doherty, DLA Troop Support - FSA, 215-737-9508. The Solicitation will be issued under authority 10 U.S.C. 2034 (c) 1, only one responsible source. Place of Performance: Contracting Office Address: 700 Robbins Avenue Philadelphia, Pennsylvania 19111-5092 United States Primary Point of Contact: Amanda Doherty Contracting Officer Amanda.doherty@dla.mil Phone: 215-737-9508